ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0061

Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways

Joshua Sciurba1, Daniel Kass1, Eleanor Valenzi2, John Sembrat2, Robert Lafyatis3 and Dana Ascherman4, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: ACR Convergence 2024

Keywords: Fibroblasts, Other, interstitial lung disease, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Transcriptional profiling represents a powerful tool for deciphering disease-relevant pathways and deriving functional biomarkers.  Given the shared demographic, genetic, and clinico-epidemiologic features between rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), we sought to demonstrate the mechanistic basis for similarities (as well as differences) between RA-ILD and IPF through comparative single cell RNA sequencing (scRNAseq) of lung tissue from these disorders.

Methods: We obtained explanted lung tissue from n=13 IPF and n=3 RA-ILD patients as well as n=10 controls (source of healthy lungs rejected for transplantation).  Following single cell isolation, RNA extraction, and cDNA amplification, we generated gene expression libraries from individual lung samples and then performed scRNAseq using the 10x Genomics’ platform.  Resulting sequences were aligned with Cellranger and clustered using the Seurat R toolkit.  This approach yielded differentially expressed genes (DEGs) in specific cell populations derived from IPF, RA-ILD, and Control lung tissue.  Gene Ontology algorithms were used for analysis of distinguishing as well as overlapping pathways represented by these DEGs. 

Results: Clustering demonstrated prominent macrophage and fibroblast populations in RA-ILD, IPF, and control lung tissue (Figure 1).   Assessment of DEGs in these cell populations (each comprised of multiple subclusters) revealed numerous DEGs separating both IPF and RA-ILD from control lung specimens.  Comparison of these macrophage- and fibroblast-derived DEGs between RA-ILD and IPF yielded a series of overlapping as well as distinct DEGs in both macrophages and fibroblasts (Figure 2). Although there were a significantly greater number of DEGs specifically associated with macrophages and fibroblasts derived from RA-ILD lung tissue (compared to IPF), a considerable percentage of IPF-associated DEGs were also represented in RA-ILD cell populations [256/478 (54%) IPF-associated macrophage DEGs and 301/426 (71%) IPF-associated fibroblast DEGs matched with RA-ILD DEGs]—highlighting the degree of transcriptional overlap between these disorders.  Key pathways derived from Gene Ontology analysis of overlapping as well as unique DEGs in RA-ILD and IPF lung tissue are shown in Figure 3.  While many of the shared DEGs represent pathways geared toward tissue remodeling and fibrosis, those DEGs distinguishing RA-ILD from IPF feature a range of both pro-inflammatory (macrophage-oriented) and pro-fibrotic (fibroblast-directed) pathways.

Conclusion: Assessment of transcriptional profiles linked to RA-ILD and IPF lung tissue demonstrates both shared and unique patterns of gene expression in these disorders. Corresponding Gene Ontology analysis highlights key pathways encompassing mediators that a) are likely to play a role in disease pathogenesis and b) should provide a template for derivation of peripheral blood biomarkers as well as selection of therapeutic targets.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Sciurba: None; D. Kass: None; E. Valenzi: None; J. Sembrat: None; R. Lafyatis: AbbVie/Abbott, 1, Bain Capital, 2, Bristol-Myers Squibb(BMS), 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Mediar, 2, Merck/MSD, 1, Modumac Therapeutics inc, 4, Pfizer, 5, Third Rock Venture, 2, Thirona Bio, 2, 11; D. Ascherman: None.

To cite this abstract in AMA style:

Sciurba J, Kass D, Valenzi E, Sembrat J, Lafyatis R, Ascherman D. Comparative Transcriptional Profiling of IPF and RA-ILD Lung Tissue Demonstrates Both Overlapping and Distinct Cell-specific Signaling Pathways [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparative-transcriptional-profiling-of-ipf-and-ra-ild-lung-tissue-demonstrates-both-overlapping-and-distinct-cell-specific-signaling-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-transcriptional-profiling-of-ipf-and-ra-ild-lung-tissue-demonstrates-both-overlapping-and-distinct-cell-specific-signaling-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology